arrow_back Back to App

Drug Control Office Reauthorization: Boosting Naloxone Access and Fentanyl Enforcement.

This Act reauthorizes the federal Office of National Drug Control Policy (ONDCP) until 2031, focusing heavily on life-saving measures and combating fentanyl. It mandates increased availability of naloxone (overdose reversal agents) for first responders and communities, while allocating specific funds and prosecutorial resources to target fentanyl traffickers. Citizens benefit from enhanced public health tools and greater government transparency regarding drug control data and surveillance programs.
Key points
Mandates increased accessibility of life-saving overdose reversal agents, such as naloxone, for local communities and emergency services.
Allocates dedicated funding (minimum $5 million annually) and prosecutorial resources to enhance the seizure and interdiction of fentanyl and target trafficking organizations.
Extends funding and increases maximum grants for local anti-drug coalitions and community prevention programs through 2031.
Requires regular public reporting on data analytical programs (like Hemisphere) to ensure activities comply with Fourth Amendment protections against unreasonable search.
article Official text account_balance Process page
VOTING RESULTS
2024-12-05
100%
For 399
Against 1
Abstain 0
Full voting results open_in_new
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_9598
Sponsor: Rep. Comer, James [R-KY-1]
Process start date: 2024-09-16
Voting date: 2024-12-05
Meeting no: 2
Voting no: 485
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-09-2025
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Office of National Drug Control Policy Reauthorization Act of 2024

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_9598.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2024-09-16.

What are the main provisions?

Key points include:

  • Mandates increased accessibility of life-saving overdose reversal agents, such as naloxone, for local communities and emergency services.
  • Allocates dedicated funding (minimum $5 million annually) and prosecutorial resources to enhance the seizure and interdiction of fentanyl and target trafficking organizations.
  • Extends funding and increases maximum grants for local anti-drug coalitions and community prevention programs through 2031.
  • Requires regular public reporting on data analytical programs (like Hemisphere) to ensure activities comply with Fourth Amendment protections against unreasonable search.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Where is the official voting record?

The official roll call vote is recorded at: voting record

Who is the primary sponsor?

The primary sponsor is Rep. Comer, James [R-KY-1].

What is the latest detailed status?

The latest detailed status is: On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 399 - 1 (Roll no. 485). (text: 12/4/2024 CR H6319-6322)

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-26.

CATEGORIES

Health Security Courts and Law